Chemokines in neuroectodermal development and their potential implication in cancer stem cell-driven metastasis by Civenni, G & Sommer, L
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Chemokines in neuroectodermal development and their potential
implication in cancer stem cell-driven metastasis
Civenni, G; Sommer, L
Civenni, G; Sommer, L (2009). Chemokines in neuroectodermal development and their potential implication in
cancer stem cell-driven metastasis. Seminars in Cancer Biology, 19(2):68-75.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Seminars in Cancer Biology 2009, 19(2):68-75.
Civenni, G; Sommer, L (2009). Chemokines in neuroectodermal development and their potential implication in
cancer stem cell-driven metastasis. Seminars in Cancer Biology, 19(2):68-75.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Seminars in Cancer Biology 2009, 19(2):68-75.
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1
Chemokines in neuroectodermal development and their potential implication in 
cancer stem cell-driven metastasis
Gianluca Civenni* and Lukas Sommer
Gianluca Civenni, Ph.D.
Cell and Developmental Biology
Institute of Anatomy
University of Zurich
Zurich, Switzerland
Winterthurerstrasse 190
CH-8057 Zurich
Phone +41 44 635 53 29
Fax +41 44 635 57 02
gianluca.civenni@anatom.unizh.ch
Lukas Sommer, Ph.D.
Cell and Developmental Biology
Institute of Anatomy
University of Zurich
Winterthurerstrasse 190
CH-8057 Zurich
Switzerland
Phone +41 44 635 53 50
Fax +41 44 635 68 95
lukas.sommer@anatom.unizh.ch
*Correspondence should be addressed to G.C. (gianluca.civenni@anatom.uzh.ch)
* Manuscript
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2
Abstract
Chemokines regulate proliferation and migration of various types of normal stem and 
progenitor cells, including precursor cells of neuroectodermal origin. Based on this it 
is conceivable that the established role of chemokines in cancer cell proliferation and 
organ specific-metastasis might also be associated with stem cell-like cells present in 
the tumor. Such cancer stem cells (CSCs) represent a small subpopulation of tumor 
cells that are thought to initiate and sustain tumor formation. More recently, 
characteristics of stem cells have also been observed in metastatic cancer cells, and it 
has been suggested that CSCs might play a crucial role in the metastatic process as 
such. Intriguingly, first evidence has been provided that the metastatic spread of 
specific CSCs is driven by chemokine signaling. Thus it is possible that chemokine-
mediated CSC regulation might be a general feature of metastasis formation.
Keywords: Neuroectoderm, CNS, neural crest, EMT, chemokines, cancer stem cells, 
metastasis.
Abbreviations: NC: neural crest; CSCs: cancer stem cells; EMT: epithelial-
mesenchymal transition; CNS: central nervous system.
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Introduction
A wealth of data suggests that chemokine signaling can contribute to tumorigenesis 
and metastases [1]. In particular, a strong correlation between chemokine receptor 
expression and organ-specific metastasis formation has been described for many 
different types of solid cancers [2-10]. It is assumed that chemokine receptor-
expressing cancer cells home to organs that express high levels of the appropriate 
ligand. Thereby, the chemokine axis involved appears to be specific both for the 
cancer cell type and the target organ. For instance, in breast cancer, expression of both 
CXCR4 and CCR7 predicts lung and lymph node metastases [11]. In melanoma, 
however, CXCR4 is highly associated with pulmonary [12,13] and liver [14]
metastasis formation, whereas CCR7 and CXCR3 were associated with lymph node 
metastases [12,15-18]. In addition, CCR10 is predominantly expressed by 
keratinocytes and associated with melanoma-derived skin metastasis [12], while 
CCR9 has been linked to small intestinal melanoma metastases [19,20]. In 
neuroblastoma, CXCR4 expression is strongly correlated with bone and bone marrow 
metastases [21,22]. Studies of Zhang and colleagues recently demonstrated an 
influence of tissue stromal cells on CXCR4 expression levels in neuroblastoma cells 
[22]. Moreover, neuroblastoma cells showed CXCR4 up-regulation when cultivated 
with liver and bone marrow preconditioned media suggesting that the specific 
microenvironment plays a pivotal role to promote metastases outgrowth [22].
Recently, however, it has been shown that CXCR4 has no significant influence on the 
number or pattern of neuroblastoma metastasis. Rather, a strong growth-promoting 
effect was observed, potentially representing the main role of CXCR4 in 
neuroblastoma progression [23]. Moreover, intracranial glioblastoma and 
medulloblastoma xenografts treated with a CXCR4 antagonist (AMD3100) showed 
reduced cell growth and increased tumor cell apoptosis [24]. Thus, although 
chemokine signaling in cancer has predominantly been associated with organ-specific 
metastasis, other cellular processes also appear to be controlled by these molecules. 
Likely, the mode of chemokine action depends on the cancer cell type affected, as cell 
intrinsic properties determine the cells response to a specific chemokine 
ligand/receptor pair. Similarly, during development, cell fates are regulated by the 
combinatorial activities of intrinsic cues and extracellular factors [25]. Therefore, 
given the parallels between tumor formation and embryonic development and in view 
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of the recent discovery of tumor-initiating cells sharing certain properties of normal 
stem cells [26], it might be valuable to consider chemokine function in cancer with 
the eyes of a developmental biologist. In this review, we will first give a brief 
overview on neuroectodermal development and discuss how chemokines affect 
precursor cells originating from the neuroectoderm and other tissues. We will then 
extend this discussion to possible associations between chemokine signaling and 
metastasizing cancer stem cells.
Precursor cells in neuroectodermal development
Development of the central nervous system (CNS) begins as an epithelial sheet called 
the neuroectoderm that is composed of primary neuroepithelial precursor cells 
displaying stem cell properties. During neurulation, the edges of this sheet fold 
together to form the neural tube, with the fluid-filled center later becoming the 
ventricular system and spinal canal. Neuroepithelial cells divide symmetrically to 
increase the pool of stem cells. Later they give rise to so-called radial glial cells that 
divide either symmetrically or asymmetrically, generating a stem cell that remains in 
the ventricular zone and a daughter cell that radially migrates outward [27]. In the 
adult mammalian brain, neural stem cells give rise to specialized cell types through 
generation of more committed transiently amplifying intermediate progenitors 
[28,29]. Neural cells with stem cell properties have been identified in four distinct 
anatomical areas of the postnatal mammalian brain: the subventricular zone below the 
lateral wall of the lateral ventricles [28], the subgranular zone in the dentate gyrus of
the hippocampus [30], and more recently also in the subcallosal zone between the 
hippocampus and the corpus callosum [31] and in the cerebellum at the boundary 
between internal granular layer and white matter [32].
A second neuroectodermal cell population, called the neural crest (NC), arises during 
development from the dorsal neural tube at the time of neural tube closure [33]. This 
highly migratory and transient population of cells gives rise to specialized cells 
throughout the body, including Schwann cells, neuronal cells of the peripheral 
nervous system (enteric, parasympathetic, sympathoadrenal, and sensory neurons), 
melanocytes in the skin, endocrine cells, and cells forming connective tissue of the 
face and neck (Fig. 1A) [33]. Initially, NC cells are a part of the neuroectodermal 
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epithelium, and thus maintain an epithelial character. Subsequently, NC cells undergo 
an epithelial-mesenchymal transition (EMT) [34], delaminate from the epithelium, 
and extensively migrate throughout the embryo before differentiation. EMT is a key 
biological process occurring during embryonic development, tissue remodeling, and 
wound repair, allowing epithelial cells to escape from the rigid structural constraints 
provided by the tissue architecture and to adopt a phenotype more permissive for cell 
migration [34]. Essentially, during this event, epithelial cells actively downregulate 
cell-cell adhesion, lose their polarity, and acquire a mesenchymal phenotype with 
reduced intercellular interactions and increased migratory capacity. EMT of NC cells 
represents a paradigmatic example during embryogenesis. During EMT, NC cells lose 
N-cadherin-mediated cell-cell adhesion while becoming excluded from the neural 
epithelium [35]. When NC cells are released from the neural epithelium, they 
concomitantly upregulate genes required for a mesenchymal phenotype and migratory 
ability. These include transcription factors such as Slug or Snail, AP-2, Foxd3, PAX3, 
Twist, Sox9, and others [36]. Furthermore, NC cell induction and delamination are 
promoted by specific signaling pathways, including BMP4 and Wnt signal activation 
[37-39].
Immediately after delamination, NC cells start to migrate either ventrally close to the 
neural tube or dorso-laterally in proximity to the somatic ectoderm [40,41]. At least a 
subpopulation of migratory NC cells display stem cell properties, being multipotent 
and able to self-renew [42]. By largely unknown mechanisms, which may depend on 
their progenitor state, NC cells stop migrating and subsequently differentiate into 
specialized cell types. However, there is multiple evidence that multipotent cells with 
stem cell features (so-called NC-derived stem cells, NCSCs) persist in NC target 
structures, including in the adult organism. Notably, cells very similar to embryonic 
NCSCs in terms of marker expression and differentiation program have been isolated 
from the adult heart [43], gut [44], bone marrow [45], and skin [46-48]. The presence 
of postnatal stem cells derived from neuroectodermal structures raises the question of 
whether such cells might contribute to the formation of neuroectodermal tumors.
Chemokines regulating neural precursor cell migration and proliferation
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The fate of CNS and NC stem cells is largely dependent on a finely tuned, stage- and 
area-specific interplay between the extracellular environment and intracellular 
regulatory cues. Various growth factors including sonic hedgehog (Shh), Wnt, and 
transforming growth factor (TGF)ß are known to control the balance between stem 
cell proliferation and differentiation both in the CNS and during NC development 
[49-51]. In addition, factors often act in combination to elicit specific cellular 
responses not achieved by the individual factors alone. For instance, Wnt together 
with BMP support maintenance and expansion of dorsal CNS stem cells and early 
migratory NCSCs, while the individual factors alone promote cell cycle exit and 
differentiation [52,53].
With respect to chemokines, comprehensive studies of neural stem cell-specific 
functions are scarce. However, several reports point to a role of chemokine signaling 
at early cellular stages, indicating an involvement in precursor cell proliferation and 
migration. Examination of embryonic neural progenitor cells in culture has confirmed 
that these cells express CXCR4 and that its unique ligand CXCL12 can act as a 
chemoattractant [54-57]. Deletion of the genes for the CXCR4 chemokine receptor or 
for CXCL12 is lethal at a relatively late stage of embryogenesis [58,59]. CXCR4 or 
CXCL12-deficient embryos exhibit a large number of phenotypes, including defects 
in the cardiovascular, gastrointestinal, and nervous systems, in addition to the immune 
system [58-61]. In the nervous system, the development of the cerebellum, 
hippocampal dentate gyrus, cortex, and dorsal root ganglia (DRG) are all affected 
[59,62-65] and deficits in the migration and proliferation of oligodendrocyte 
progenitors have also been observed [66,67]. The expression patterns of CXCL12 and 
CXCR4 during embryogenesis [68,69] indicates that all of these developmental 
phenotypes could possibly be explained on the basis of deficits in CXCL12-mediated 
attraction of embryonic neural precursor cells. This is best illustrated by the cerebellar 
phenotype of CXCL12 and CXCR4 knockout mice [58,59]. During development of 
the cerebellum, cerebellar granule cell progenitors are restricted to the external 
granule cell layer, where they proliferate. Once the pool of progenitors has expanded, 
post-mitotic cells migrate to the internal granule cell layer, the normal location for 
mature granule cells. In CXCR4 and CXCL12-deficient mice granule cell progenitors 
proceeded with their migration at an improperly early time, causing the progenitors to 
locate ectopically within the Purkinje cell layer. In this system, CXCL12 signal 
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maintains progenitors within the external granule cell layer [70,71]. Upon inactivation 
of CXCR4 the progenitors escape the confines of the external granule cell layer, 
leading to their inappropriately early migration. 
Similarly, in the hippocampal dentate gyrus, deletion of CXCR4 results in ectopically 
placed granule cells along the normal way of granule cell progenitor migration 
[62,63]. Granule cell progenitors move from the wall of the lateral ventricle 
immediately after birth driven by meningeal cells secreting CXCL12. Abolishing 
CXCR4 expression on the granule cell progenitors, therefore, delays migration, 
explaining the observed phenotype. Other neuronal phenotypes apparent in CXCR4 
knockout mice include defects in the placement of a specific subpopulation of 
forebrain neurons, Cajal–Retzius cells, and cortical GABAergic interneurons [64,72-
75]. In all of these situations, the progenitors for these neurons employ CXCL12-
mediated chemoattraction to accomplish their final positioning, and lack of CXCR4 
signaling results, therefore, in interrupted progenitor migration. 
During NC cell development, the chemokine CCL5 (RANTES) has been described to 
drive migration of primary neurons in DRGs [76]. Similarly, CXCR4 expressed on 
migratory cells regulates migration of NC-derived sensory neuronal progenitor cells 
into DRGs (Fig. 1B) [65]. CXCR4 or CXCL12 are also involved in cardiac 
development. During development of the heart, a subpopulation of cardiac NC cells 
migrate to colonize the outflow tract endocardial cushions prior to septation, the 
process through which a single outflow vessel, the truncus arteriosus, develops into 
the ascending aorta and the pulmonary trunk [77]. However, in both CXCR4 and 
CXCL12-deficient mice the region of the ventricular septum is abnormal [59,78]. 
Since CXCL12 is expressed in the developing heart tissue [68] and CXCR4 is 
expressed in migrating cells of the NC [65], it is conceivable that disrupted ‘homing’ 
of mutant cells to their target organ brings about this phenotype (Fig. 1B), consistent 
with the defects observed in CXCR4-mutant DRG. Likewise, mutation of CXCL12, a 
chemoattractant for NC-derived melanophores in zebrafish, results in ectopic 
melanophore migration and disturbed pigment patterning in this system (Fig. 1B)
[79].
Apart from migration, chemokine signaling can also influence the number of neural 
precursor cells. For instance, CXCL12 is a mitogenic cue for postnatal mouse neural 
progenitor cells [80] and various human neural progenitor cell lines [81]. However, in 
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human hippocampal neural precursors, CXCL12 has also been reported to promote 
survival and maintenance in a quiescent state, rather than inducing cell cycle 
progression [54]. The use of cell lines from different stages or brain areas might 
possibly explain the discrepancy between these studies, which emphasizes again that 
one and the same chemokine can elicit different effects in distinct cell types of 
neuroectodermal origin.
The role of chemokines in regulating precursor cell development is not exclusive to 
the nervous system. Functional CXCR4 is found on the surface of several tissue 
committed stem/progenitor cells, such as haematopoietic stem cells [82], primordial 
germ cells [83], skeletal muscle satellite progenitor cells [84], liver progenitor cells 
[85], and retinal pigment epithelium progenitors [86]. Functional CXCR4 is also 
expressed on murine embryonic stem cells. In mice deficient for CXCL12 or CXCR4, 
primitive hematopoietic stem cells fail to localize to the bone marrow, the site of 
hematopoiesis at postnatal stages [58,59]. A further interesting phenotype identified 
in CXCL12/CXCR4 knockout mice is a deficiency in blood vessel development, as 
initially observed in the gastrointestinal system [60]. Consistent with these 
observations, CXCR4 is expressed by hemangioblasts [87] and endothelial cells 
derived from embryonic stem cells in culture [88]. In the latter situation the 
endothelial cells expressed CXCR4 and migrated towards a CXCL12 gradient. 
Therefore, there is strong indication that CXCR4 signaling in endothelial progenitors 
has a substantial impact on vascularization in the embryo. Finally, analysis of 
primordial germ cell migration in zebrafish, in which genes for CXCL12 or CXCR4 
have been deleted, shows aberrant colonization of the gonads by these cells [89]. The 
combined data suggest that chemokine signaling might play a general role during 
tissue regeneration and repair, e.g. by chemoattraction of CXCR4-positive stem or 
progenitor cells to a specific tissue.
Cancer stem cells in neuroectodermal tumors
The fundamental functions of chemokines in spread and proliferation of normal stem 
and progenitors cells raises the hypothesis that chemokines might elicit similar effects 
in specific cancer cell subpopulations, the so-called cancer stem cells (CSCs). 
Growing evidence over the past few years has revealed that distinct populations of 
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cancer cells with features of stem cells play a crucial role in the development and 
progression of tumors [90,91]. As currently defined, a CSC represents a cell within a 
tumor that is able to self-renew in vitro and in vivo, is exclusively tumorigenic even at 
low cell numbers, and is capable of reproducing the cellular heterogeneity found in 
the parental tumor [90]. Therefore, it should be achievable to identify the cells 
responsible for de novo tumor formation based on their distinct phenotypic and 
functional characteristics [92]. Indeed, tumor-initiating CSCs with specific properties 
and marker expression have been identified in several malignancies including blood, 
skin, breast, ovarian, prostate cancers, and neuroectodermal tumors [93-105].
As their name implies, neuroectodermal tumors arise from adult tissue originating 
from the embryonic neuroectoderm. As derivatives of CNS cells, neuroectodermal 
tumors include medulloblastoma, oligodendroglioma, oligodendrocytoma, and 
astrocytoma. Another class of neuroectodermal tumors have a NC cell origin and 
comprise, among others, neurofibroma, schwannoma, neuroblastoma, malignant 
nerve sheath tumor, and melanoma [106,107]. Clinically, the classification of 
neurological tumors is based on the predominant cell type(s), which is generally 
determined by morphological and immunohistochemical criteria (Fig. 2). Although 
not all neuroectodermal neoplasms have yet been shown to contain CSCs, the 
existence of brain tumor stem cells has, for instance, been described for both adult 
and pediatric gliomas and for malignant medulloblastomas [108-110]. Interestingly,
CSCs from these brain tumors express many genes characteristic of CNS stem cells, 
including Sox2, musashi-1, bmi-1, and CD133 (Prominin-1) [109-111].
An involvement of CSCs in tumor initiation and progression, chemoresistance and 
therapeutic failure has also been reported for human melanoma, the most fatal skin 
cancer [112-117]. Similar to normal tissues, melanomas consist of phenotypically 
heterogeneous cell populations in accordance with the idea that these tumors arise 
from multipotent cells [112,113,118-120]. Indeed, various cell culture and in vivo
transplantation experiments indicated the existence melanoma cell subpopulations 
with stem cell-like differentiation capacity and increased tumorigenic potential 
[112,116,120]. Thus, malignant melanoma stem cells may contribute to natural 
progression and therapeutic failure in this disease.
Despite the growing evidence for CSCs underlying neuroectodermal tumor formation, 
their cellular origin remains unclear. One possibility is that they arise by 
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transformation of neural stem cells. Concurring with this hypothesis, normal CNS 
stem cells can be found in the adult brain, and NCSCs associated with the 
melanocytic lineage are present in the skin, the site of melanoma formation [29,48]. 
Nonetheless, CSCs could also arise by de-differentiation upon transformation of more 
mature cells. For instance, normal pigmented melanocytes can give rise to less 
differentiated cells, although these have a somewhat more limited potential than 
NCSCs [121]. Recently, neurofibroma –a tumor arising around peripheral nerves– has 
been suggested to develop from differentiated adult cells rather than stem cells 
[122,123]. Neurofibroma is caused by a defective version of the protein 
neurofibromin (NF1) that normally acts as a brake preventing cells in the nervous 
system from overproliferation [106]. Neurofibromas are composed of a mixture of 
cells, consistent with an involvement of a multipotent cell in tumor formation. 
However, NF1-mutant NCSCs differentiate into the expected cell types and are 
unable to initiate tumor formation upon transplantation into adult nerves [122]. 
Moreover, inactivation of the NF1 gene induced a marked increase in proliferation of 
non-myelinating Schwann cells rather than of undifferentiated stem cells [123]. Still, 
these data do not exclude that other tumors, as for instance melanoma, might originate 
from transformation of normal stem cells, as it is well conceivable that different 
tumor types with different aggressiveness might arise from distinct cell types.
Chemokines in cancer stem cells and metastasis
CSCs may not only be associated with tumor initiation and growth but also with 
metastasis formation: if CSCs represent the only cell population with tumor-initiating 
potential, one would hypothesize that solely CSCs are capable of generating tumor 
metastases [124]. It has even been proposed that cancer cells adopt stem cell features 
only upon undergoing EMT. Indeed, induction of EMT in immortalized human 
mammary epithelial cells resulted in the expression of stem-cell markers, the gain of 
mesenchymal behavior, and phenotypes associated with CSCs [125]. These findings 
illustrated a direct link between EMT and gain of properties characteristic for 
migratory stem cells (Fig. 3). It remains to be shown, however, whether this is a 
general phenomenon of metastasis formation. For instance, in tumors derived from 
NC structures, CSCs in primary tumors might share properties with normal NCSCs 
that are already endowed with an intrinsic capacity to migrate. This hypothesis could 
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offer an explanation for why neuroectodermal tumors of NC cell origin, such as 
melanoma, are highly metastatic and aggressive. 
As mentioned above, EMT is characterized by the expression of various factors 
responsible for mediating this process at the molecular level. It is interesting but not 
surprising that many of these molecules have also been associated with tumor 
progression [126]. Little is known regarding the type of EMT induced by chemokine 
system(s) despite abundant evidence of the diverse malignant behaviors of such 
systems in cancer cells. In a model of EMT in colon carcinoma an upregulation of 
CXCL8 and its cognate chemokine receptor CXCR1 has been observed. In this study, 
both CXCL8 and CXCR1 were involved in the chemokinetic and chemotactic 
migration of colon carcinoma cells as assessed by antibody inhibition, establishing 
that the regulated expression of a specific chemokine and its receptor are linked to 
EMT [127]. Similarly, Onoue and colleagues demonstrated that CXCL12/CXCR4 
signaling induces EMT in oral squamous cell carcinoma (SCC) [128]. In addition, it 
has been suggested that EMT induced by the CXCL12/CXCR4 system might also be 
involved in lymph node metastasis of oral SCC [4]. 
From a functional perspective, these studies highlight that two chemokine/chemokine-
receptor systems (CXCL8/CXCR1 and CXCL12/CXCR4) are associated with EMT 
and linked with a more invasive tumor cell phenotype. Given the likely involvement 
of CSCs in metastasis and the roles of chemokines both in metastasis and in normal 
precursor cell migration and proliferation it follows that chemokines could 
specifically drive metastasis of CSCs. Not until very recently, though, experimental 
evidence for this has been provided [96]. Human pancreatic cancer tissue contains 
CSCs expressing CD133 that are tumorigenic and highly resistant to standard 
chemotherapy. Remarkably, in the invasive front of pancreatic tumors, a distinct 
subpopulation of CD133+/CXCR4+ CSCs was identified that appears to determine the 
metastatic phenotype of the individual tumor. Depletion of the CSC pool for this 
migrating CSC subpopulation effectively abrogated the metastatic capacity of 
pancreatic cancer cells without affecting their tumorigenic potential [96]. In this 
study, Hermann and colleagues for the first time demonstrated that not only CSCs are 
underlying metastasis formation, but that expression of a chemokine receptor defines 
a metastatic subpopulation within the CSC pool. Moreover, at least in breast cancer, 
CXCR4 expression appears to correlate with the CSC content, and thus the 
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aggressiveness, of cancer cell lines. For example, relative to non-metastatic MCF-7 
breast cancer cells, highly metastatic MDA-MB-231 cells have a larger proportion of 
CSCs and express higher levels of CXCR4 [129]. All together, these results suggest 
that CSCs may indeed be involved in metastasis formation and, furthermore, be 
partially controlled by chemokine signaling (Fig. 4). These preliminary data together 
with the reported role of various chemokines in metastasis strongly support the idea 
that migrating CSCs could play a key function in chemokine-mediated metastasis of 
cancer. Interestingly, AMD3100, a specific pharmacological inhibitor of the CXCR4 
receptor, strongly inhibits metastatic activity of unselected murine pancreatic cancer 
cells [130] as well as purified CSCs [96], and the fact that AMD3100 is already 
evaluated in ongoing clinical trials make it a candidate for further experimental 
studies on CSC-mediated metastasis [131,132].
Conclusion
In recent years, the field of cancer research has gained many novel insights into the 
cellular and molecular processes underlying tumor growth, dissemination of tumor 
cells, and metastasis. Tumor-initiating cancer cells with stem cell properties have 
been identified in a wide range of cancers including several neuroectodermal tumors, 
and there is good evidence that CSCs might be implicated in the generation of 
metastases. This model would also explain the low efficiency of the metastatic 
process, since only a small fraction of cells would be responsible for initiating and 
sustaining a new metastatic lesion. However, there remain at least as many questions 
to be addressed as have been resolved to date. In pancreatic cancer –the only tumor 
for which a direct association between CSCs, chemokine signaling, and metastasis has 
been provided so far– the CSC in question was reported to express the stem cell 
marker CD133 [96]. However, in colon cancer, cells negative for CD133 recently 
turned out to have a metastatic potential comparable to the one of CD133-positive 
cells, and metastatic CD133-negative cells form even more aggressive tumors [133].
In melanoma, several markers have been associated with stem cells 
[112,116,117,120], but a strict correlation between marker expression, self-renewal, 
and high tumorigenicity remains to be established [105]. Likewise, the exact identity 
and biological features of metastatic cells from melanoma or other neuroectodermal 
tumors are unknown. Such knowledge will be necessary, though, to be able to 
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understand the mode of action of factors influencing cancer cell metastasis, because 
these cues act for sure in cell type and context-specific manners. To this end we 
propose to thoroughly consult developmental biology and to elucidate the nature of 
normal stem cells, and the mechanisms controlling their proliferation and migration, 
as a basis for the study of tumor biology. Indeed, metastatic cells appear to share 
many similarities with normal stem cells, including the use of chemokine signaling 
for migration and proliferation. It would thus stand to reason that chemokine signaling 
plays a pivotal role in CSC-driven metastasis. Efforts should be undertaken to address 
this hypothesis, because if confirmed, chemokines and their receptors would represent 
a powerful target for eradicating metastasis formation.
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Figure Legends
Fig. 1: Neural crest migration and chemokines. A, Neural crest cells arise from the 
dorsal part of the neural tube. Subsequently, they migrate through the tissue of the 
developing embryo and differentiate into a wide array of cell types, including neurons 
and glia of the peripheral nervous system, cartilage and bone of the face, connective 
tissue, and melanocytes. B, Chemokine signaling regulates proper migration of neural 
crest cells that give rise to sensory neurons of the dorsal root ganglia (DRG) and 
smooth muscle cells in the outflow tract of the heart in mammalian. Melanophores in 
zebrafish also rely on chemokine signaling for correct migration.
Fig. 2: Developmental scheme of neuroectodermal cells and the classification of 
neuroectoderm-derived tumors. A, Multipotent neural stem cells in the 
ventricular/subventricular zones of the embryonic neural tube give rise to three main 
cell types in the mature CNS: neurons, oligodendrocytes, and astrocytes. The 
classification of neurological tumors is based on their predominant cell type(s). 
Astrocytoma is composed primarily of astrocytes, oligodendroglioma is composed 
primarily of oligodendrocytes, and oligoastrocytoma contains both astrocytic and 
oligodendroglial components. B, Neural crest cells are neural tube-derived 
multipotent stem cells, which give rise to various cell types. Neuroblastoma mainly 
occurs in children and originates from the sympathoadrenal lineage. Neurofibroma is 
a heterogeneous tumor that contains Schwann cells, fibroblasts, perineural cells, and 
neuronal cells. Schwannoma is a more homogeneous tumor that is composed of 
Schwann cells. Note that the arrows indicate a lineage relationship and do not imply 
that tumor cells arise from differentiated cells. In fact, tumors could originate from 
transformation of stem and/or progenitor cells.
Fig. 3: Cancer stem cells in metastasis formation. A, Progressive epigenetic and 
genetic alterations drive the transformation of normal human cells into malignant 
cancer stem cells (CSC, red), which generate locally a tumor. Additional changes lead 
to a local dissemination of CSCs, possibly via an epithelial-mesenchymal transition 
(EMT). The migrating cells intravasate into lymph or blood vessels. The cells are 
passively transported to distant organs, where single cells can extravasate and form a 
new tumor via a mesenchymal-epithelial transition (MET). B, An alternative model 
suggests that CSCs are generated in primary tumor from cancer cells during EMT 
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[125].
Fig. 4: Potential implication of cancer stem cells in metastasis. The CSC model 
assumes that intra-tumor heterogeneity is mainly caused by cell differentiation and 
that only CSCs (red), but not differentiated cells, emigrate and form metastases. In the 
CSC model, metastatic cancer cells undergo differentiation programs that closely 
resemble those observed in the corresponding primary tissue. As in normal stem cells, 
chemokine signaling may drive migration, and thus metastasis, of CSCs.
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